Link to this page
Physician Data Query
| Preferred Name | erlotinib hydrochloride | |
| Synonyms |
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine monohydrochloride OSI774 Tarceva CP-358,774 CP358774 OSI-774 |
|
| Definitions |
The hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2693" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2693" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038428 |
|
| altLabel |
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine monohydrochloride OSI774 Tarceva CP-358,774 CP358774 OSI-774
|
|
| CAS Registry |
183319-69-9
|
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000433189 http://purl.bioontology.org/ontology/PDQ/CDR0000409775 http://purl.bioontology.org/ontology/PDQ/CDR0000256413 http://purl.bioontology.org/ontology/PDQ/CDR0000257391 http://purl.bioontology.org/ontology/PDQ/CDR0000305923 http://purl.bioontology.org/ontology/PDQ/CDR0000373810 http://purl.bioontology.org/ontology/PDQ/CDR0000352306 http://purl.bioontology.org/ontology/PDQ/CDR0000441005 http://purl.bioontology.org/ontology/PDQ/CDR0000038548 http://purl.bioontology.org/ontology/PDQ/CDR0000038465 http://purl.bioontology.org/ontology/PDQ/CDR0000357522 http://purl.bioontology.org/ontology/PDQ/CDR0000256414 http://purl.bioontology.org/ontology/PDQ/CDR0000271336 http://purl.bioontology.org/ontology/PDQ/CDR0000407440 http://purl.bioontology.org/ontology/PDQ/CDR0000385655 http://purl.bioontology.org/ontology/PDQ/CDR0000256419 http://purl.bioontology.org/ontology/PDQ/CDR0000038594 http://purl.bioontology.org/ontology/PDQ/CDR0000407439 http://purl.bioontology.org/ontology/PDQ/CDR0000038513 |
|
| cui |
C1135137 C0910101 C1533491 C1135136
|
|
| Date last modified |
2017-10-11
|
|
| definition |
The hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2693" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2693" NCI Thesaurus)
|
|
| IND Code |
63383
|
|
| Legacy PDQ ID |
11045
|
|
| LT |
TRD
|
|
| NCI ID |
C2693
|
|
| notation |
CDR0000038428
|
|
| NSC Code |
718781
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
erlotinib hydrochloride
|
|
| tui |
T109 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |